Intravenous immunoglobulin in the treatment of primary immunodeficiency diseases

Deirdre De Ranieri*, Nana Sarkoah Fenny

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

Intravenous immunoglobulin (IVIG) has been used as antibody replacement therapy in primary immunodeficiency diseases (PIDDs) for more than 50 years. Its role as a therapeutic agent has expanded over the past couple of decades as its anti-inflammatory and immune-modulatory mechanisms of action have been elucidated. It is now used “off-label” to treat other autoimmune diseases. This article focuses on the role of IVIG in the treatment of PIDDs characterized by absent or deficient antibody production. Replacement doses are given on a monthly basis in these conditions as a prophylactic measure to prevent acute and serious bacterial infections.

Original languageEnglish (US)
Pages (from-to)e8-e12
JournalPediatric annals
Volume46
Issue number1
DOIs
StatePublished - Jan 2017

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Fingerprint

Dive into the research topics of 'Intravenous immunoglobulin in the treatment of primary immunodeficiency diseases'. Together they form a unique fingerprint.

Cite this